Compare Micron Technology, Inc. (MU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Twist Bioscience Corp — how do they compare? Micron Technology, Inc. trades at $1,018.24 (market cap $1.13T), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Micron Technology, Inc. is far larger — about 134.2× Twist Bioscience Corp's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| MU | TWST | |
|---|---|---|
Market Cap | $1.13T | $8.42B |
Sector | Technology | Health |
52-Week High | $1.21K | $153.10 |
52-Week Low | $140.00 | $24.16 |
Enterprise Value | $1.11T | $8.35B |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% today but remains in a strong uptrend, supported by bullish technical signals and robust fundamentals. The company reported Q1 2026 EPS of $25.11, beating estimates by 20%, with revenue surging to $37.38 billion in 2025. Operating cash flow hit $17.53 billion, while analyst consensus is strongly bullish with an 82.9% buy rating and a $1,550 price target.
Outlook is positive due to AI-driven memory demand, with 2026 revenue projected at $90.3 billion. Risks include memory market cyclicality and supply constraints, but Micron's margin expansion and institutional support suggest further upside for investors seeking growth in semiconductor equities.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
